中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

329 records (took 0.032 seconds)

    METHODS AND COMPOSITIONS FOR PRODRUG FORMS OF SPECTINOMYCIN AND SPECTINAMIDE ANALOGS
    93.
    发明申请
    METHODS AND COMPOSITIONS FOR PRODRUG FORMS OF SPECTINOMYCIN AND SPECTINAMIDE ANALOGS 有权

    公开(公告)号：US20210388012A1

    公开(公告)日：2021-12-16

    申请号：US17288493

    申请日：2018-11-05

    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

    Inventor： Richard E. LEE ,  Jiuyu LIU

    IPC: C07F9/6561 ,  C07D493/04 ,  A61K45/06

    Abstract: In one aspect, the disclosure relates to substituted spectinomycin analogs, including substituted aminomethyl spectinomycin analogs and substituted spectinamide analogs, with increased tolerability and safety, including improved tolerability to parenteral administration. The present disclosure further pertains to methods of making disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating microbial infections using the disclosed compounds, including methods of treating antibiotic resistant infections and tuberculosis. This abstract is intended as a scanning tool for pur-poses of searching in the particular art and is not intended to be limiting of the present disclosure.

    Nucleic acid molecules containing spacers outside ITR
    95.
    发明授权
    Nucleic acid molecules containing spacers outside ITR 有权

    公开(公告)号：US11103597B2

    公开(公告)日：2021-08-31

    申请号：US15573684

    申请日：2016-05-13

    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

    Inventor： John T. Gray

    IPC: C12N15/86 ,  A61K48/00 ,  A61K35/76 ,  C12N7/00 ,  C12N15/861

    Abstract: The present invention relates to nucleic acid molecules containing spacers that can be packaged into viral particles and methods of producing them. In a first aspect, the invention features a nucleic acid molecule including a first spacer (SSI); a first inverted terminal repeat (ITR1); a cloning site (CS); a second inverted terminal repeat (ITR2); and a second spacer (SS2), such as a eukaryotic spacer; operably linked to each other in a 5′-to-3′ direction as: SS1-ITR1-CS-ITR2-SS2. In an embodiment, the invention features a vector comprising any of the above-described nucleic acid molecules. In another aspect, the invention features a plurality of viral particles including the nucleic acid molecule. The invention further includes a host cell including any of the above-described vectors.

    USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS
    96.
    发明申请
    USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS 有权

    公开(公告)号：US20210230545A1

    公开(公告)日：2021-07-29

    申请号：US17258533

    申请日：2019-07-08

    Applicant: St. Jude Children's Research Hospital

    Inventor： Caitlin Zebley ,  Hossam Abdelsamed ,  Benjamin Youngblood

    IPC: C12N5/0783 ,  C07K14/725 ,  C12Q1/6876 ,  A61K35/17

    Abstract: Provided herein are methods and compositions for modulating T-cell activity by incubating a CD8 T cell with a signal 3 cytokine, such as IL-12. Incubation of naïve CD8 T cells, particularly, with a signal 3 cytokine can acquire long-lived memory associated gene expression characteristic of the stem cell memory subset of CD8 T cells. Further, incubation with signal 3 cytokines can induce changes to the epigenetic profile of naïve CD8 T cells that are more characteristic of bona fide Tscm cells than in vitro generated cells using traditional differentiation protocols. On account of epigenetic profiles being preserved during in vivo homeostasis, signal 3 cytokines such as IL-12 can be used to engineer a T cell population with the desired epigenetic profile that maintains effector functions and proliferative capacity.

Patent Agency Ranking